by Certifié Conforme | 8 Apr Wed | English
This record closing is the largest raise ever achieved by a fully independent European fund dedicated to Biopharma, validating Jeito’s patient-driven investment strategy, its multidisciplinary, collaborative expertise spanning from science to commercialization of...
by Manon FRACHON | 15 Oct Wed | English
Paris, France, October 15th, 2025 – Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to biopharma, today announced the promotion of Ksenija Pavletic to General Partner, reinforcing the firm’s senior leadership team as it continues to...
by Manon FRACHON | 10 Sep Wed | English
Investment will support Odyssey’s portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseases. Jeito will leverage its global network, expertise and strong value creation track record in immunology and...
by Manon FRACHON | 2 Jun Mon | English
Pascal Touchon will reinforce Jeito’s expertise by bringing over 35 years of global experience in drug development, commercial activities, operational and strategic leadership at major international pharmaceutical groups and biotech companies. He will support...
by Manon FRACHON | 21 May Wed | English
Proceeds from the financing will advance ReproNovo’s lead candidates RPN-001 (leflutrozole) and RPN-002 (nolasiban), through Phase 2 clinical trials in male infertility and in the treatment of adenomyosis and embryo implantation, respectively. In the context of...
by Certifié Conforme | 13 May Tue | English
Proceeds will support two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C disease and GM1/GM2 gangliosidoses, three forms of rare lysosomal storage disorders, as well as expanding Azafaros pipeline to other indications The...
Recent Comments